As epitalon has been shown to bind to H1 (Khavinson et al 2020) it is possible that peptide may downregulate telomerase in cancer cells (through H1 binding and H19 upregulation), and activate ALT (through protein trapping) at the same time
doi: 10.1097/PRS.0b013e31828275b7
IGF-1 LR3 is for research use only and has not been approved by the FDA for human therapeutic applications
Anything injectable sold today is either an outsourcing-facility product (503B, different rules, currently no 503B authorization for GHK-Cu either), a clinical-trial supply, or a research chemical being misrepresented as a pharmaceutical product
The issue is the expectation, not the peptide
And let me just say, when I dug into the literature, I got genuinely excited